Biocon’s two manufacturing sites in Bangalore, India were inspected back in September 2019 by the US Food and Drug Administration (also known as FDA).
The two manufacturing facilities are used to manufacture drug products for two biosimilars, Trastuzumab and Pegfilgrastim.
The company has recently announced that they have now been given the all-clear sign through the concluding receipt of an establishment inspection report of the inspection.
Earlier this year, Biocon Biologics has received over $70 Million investment fund by True North in support of its biosimilars ventures, the injection of cash values the business at almost $3 Billion.
Biocon Biologics has been aggressively growing as more and more companies see potential in biosimilars.